MRM Health Receives CTA Approval for Phase 1b/2a Trial with MH002 in Ulcerative Colitis

Published on
3 weeks ago

MRM Health have received regulatory approval from the Federal Agency for Medicines and Health Products (FAMHP) in Belgium to start a Phase 1b/2a trial with the novel next-generation optimized consortium therapy, MH002, in patients with mild-to-moderate ulcerative colitis (UC). MH002 is the first rationally-designed consortium therapy, in which key disease-driving mechanisms guide therapeutic microbial strain selection, to enter clinical studies in patients.